J.P. Morgan
Healthcare
Conference
David J. Endicott
Chief Executive Officer
January 14, 2025
Alcon at a glance
Alcon
at a glance
Alcon 2023 sales:
$9.4 billion*
Alcon offers the widest array of surgical equipment, ocular health products and contact lenses in the industry. We touch millions of lives in over 140 countries.
Our Surgical products rank number one in market position globally. Our Vision Care products are among the world's most trusted.
Our research, grant and training programs help advance eye care around the world.
Total eye care market:
$34 billion*
REFRACTIVE | PRESBYOPIA | DRY EYE | CATARACTS | DIABETIC | GLAUCOMA |
ERRORS | (1.8 billion | (1.4 billion | (65 million with | RETINOPATHY | (103 million |
(153 million | sufferers2) | sufferers3) | moderate-to-severe | (146 million sufferers2) | sufferers4) |
uncorrected1) | vision impairment from | ||||
cataracts2) |
1. Source: World Health Organization. Online Q&A. 7 October 2013. 2. Source: World Health Organization. World report on vision. 2019. 3. Source: Market Scope: 2020 Dry Eye Products Market | |
Report. 4. Source: Market Scope: 2021 Glaucoma Surgical Device Market Report. | |
* This presentation references 2023 market data and full-year sales figures. In this document, references to the "eye care market" are to the Surgical and Vision Care markets in which we participate, | 4 |
including the sale of ophthalmic surgical devices, contact lenses and ocular health products, but not including the sale of spectacles and prescription ophthalmic pharmaceutical products other than |
glaucoma pharmaceutical products.
Alcon strategy: we focus on eye care
We create value by applying specialty market knowledge and specialty technical knowledge to create products that improve sight
Attract, develop and retain experts in eye care
customers and technology
Reinvest in R&D | Leverage expertise |
and product | to invent or acquire |
development | innovative products |
Commercialize globally | Create data that |
and create a superior | demonstrate |
customer experience | value and drive access |
5
Vision Care Innovation
Significant Vision Care product flow in recent years
Vision Care innovation
2021-2024
for Astigmatism | Sphere |
Complete, Ultra and | |
Hydration MDPF | Sphere, for Astigmatism, |
Multifocal |
2025-2026
AR-15512 | Multifocal Toric |
(Acoltremon, Dry Eye) |
List is not exhaustive. New product launches may not be listed in chronological order. See Safe harbor statement and the assumptions underlying our outlook for more information;
Systane nano-lipids + Hyaluronic Acis image is concept image and not final.
7
Introducing a new, weekly modality: Precision7
Start and end every week fresh
$B Sell-in by modality 10.8
Monthly | 2.8 | ||||
(26%) | |||||
2-Week | 1.4 | ||||
(13%) | |||||
DD SiHy | 4.2 | ||||
(39%) | |||||
DD non-SiHy (Value) | 2.4 | ||||
(22%) | |||||
20241 |
- Global CLI Q3 2024, MAT Q4-23 to Q3-24 sales including Cosmetic. GfK Q1 2024 Point of Sales for available countries. GfK $ shares used to approximate CLI sell in DD SiHy DD Non SiHy splits and Alcon sell in market share
- In a 2-week prospective clinical study in the US; n=181; CLEAR CARE® Cleaning & Disinfecting Solution used for cleaning and disinfection; Alcon data on file, 2023. (p=0.0353). Based on agreement to "The lenses felt comfortable - even when looking at my smart phone or computer screen for an extended period of time" as measured at 16 hours on Day 7 for PRECISION7 and Day 14 for ACUVUE OASYS 2-week lenses
- Phan CM, Chan VWY, Drolle E, et al. Evaluating the in vitro wettability and coefficient of friction of a novel and contemporary reusable silicone hydrogel contact lens materials using an in vitro blink model. Cont Lens Anterior Eye. 2024.
8
AR-15512: The only eye drop that rapidly increases natural tears
AR-15512 (Acoltremon Ophthalmic Solution 0.003% ) is an investigational product and is pending US FDA approval
AR-15512
AR-15512 is a first-in-class TRPM8 agonist
(neuromodulator) that stimulates corneal nerves to
rapidly increase natural tear production
Delivers rapid onset as early as day 1 and sustained through day 90
Up to 80% of patients achieved normal tear production at day 1
Consistent improvement in dry eye disease symptoms at 1 month with favorable safety & tolerability
PDUFA date: May 30th, 2025
9
Systane innovation underpins continued YoY double-digit growth
SYSTANE PRO PF: THE ONLY MDPF TRIPLE-ACTION FORMULA
10+ hours of symptom relief
Triple action dry eye relief with hyaluronate (HA)
Hydrates, restores & protects for all types of dry eye
SYSTANE GLOBAL GROWTH1 VS. PRIOR YEARS
16% | 15% | ||
14% | |||
10% | 10% |
2019 | 2021 vs. | 2022 | 2023 | 2024 YTD |
2019 |
1. Constant currency growth | 10 |
Attention: This is an excerpt of the original content. To continue reading it, access the original document here. |
Attachments
- Original document
- Permalink
Disclaimer
Alcon AG published this content on January 14, 2025, and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on January 15, 2025 at 01:58:02.137.